Spast is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{infobox-gene
| gene_symbol = SPAST
| gene_name = Spastin
| chromosomal_location = 2p22.3
| ncbi_gene_id = 6683
| omim_id = 604271
| ensembl_id = ENSG00000121594
| uniprot_id = Q9UBU2
| associated_diseases = Hereditary Spastic Paraplegia, Amyotrophic Lateral Sclerosis
| protein_product = Spastin (AAA ATPase)
}}
SPAST encodes spastin, a member of the AAA (ATPases Associated with diverse cellular Activities) family of ATPases. Spastin is a microtubule-severing enzyme critical for axonal transport and the dynamics of the cytoskeleton. Mutations in SPAST cause the most common form of autosomal dominant hereditary spastic paraplegia (HSP), known as SPG4.
Spastin is a microtubule-severing protein that plays essential roles in:
Microtubule Dynamics: Spastin severs and reorganizes microtubules, enabling:
Endosomal Trafficking: Spastin participates in:
Nuclear envelope maintenance: Spastin localizes to the nuclear envelope where it helps maintain nuclear membrane integrity.
Synaptic function: In neurons, spastin is involved in:
The protein contains:
| Aspect | Details |
|---|---|
| Inheritance | Autosomal dominant |
| Prevalence | ~40% of all autosomal dominant HSP cases |
| Mutations | Over 200 pathogenic variants identified |
| Mechanism | Loss of function - haploinsufficiency |
Clinical Features:
Pathogenic Mechanisms:
SPAST mutations have been reported in some ALS cases, suggesting overlapping mechanisms between HSP and ALS. The common pathway involves:
| Disease | Relationship |
|---|---|
| Parkinson's Disease | Altered spastin expression in some PD models |
| Alzheimer's Disease | Potential role in microtubule dynamics in AD |
| Charcot-Marie-Tooth Disease | Some overlap with hereditary neuropathies |
Spastin is widely expressed in the nervous system:
| Strategy | Status | Description |
|---|---|---|
| Gene therapy | Preclinical | AAV-mediated gene delivery |
| Microtubule stabilizers | Research | Baclofen, taxol derivatives |
| Antisense oligonucleotides | Research | Targeting mutant allele |
| Mitochondrial protectants | Research | CoQ10, other antioxidants |
Hazan J, et al. (1999). "Spastin, a new AAA protein, is mutated in autosomal dominant hereditary spast paraplegia." Nat Genet 23(3):296-303. PMID:10645978
Errico A, et al. (2002). "Spastin participates in axonal outgrowth and axonal maintenance." EMBO J 21(12):3155-3165. PMID:12065421
Zhang C, et al. (2019). "Spastin deficiency leads to accumulation of abnormal mitochondria and neuronal dysfunction." Acta Neuropathol Commun 7(1):222. PMID:31856877
Martignoni M, et al. (2021). "Spastin mutations in hereditary spastic paraplegia: genotype-phenotype correlation." J Neurol Sci 429:118028. PMID:34598012
Parker SG, et al. (2020). "AA+ ATPase spastin in health and disease: relationship to microtubule dynamics and neuronal function." Cell Mol Life Sci 77(23):4851-4870. PMID:32889576
Charvin D, et al. (2022). "Therapeutic approaches for hereditary spastic paraplegia." Neurology 99(7):287-298. PMID:35851582
Solowska JM, et al. (2018). "Understanding the role of spastin in microtubule dynamics and axonal transport." Mol Neurobiol 55(9):7370-7382. PMID:29368182
Roll-Mecak A, et al. (2010). "The atomic footprint of the spastin conformational change." Nat Struct Mol Biol 17(10):1221-1227. PMID:20852644
The study of Spast has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.